<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03309943</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00083809</org_study_id>
    <nct_id>NCT03309943</nct_id>
  </id_info>
  <brief_title>Neurobehavioral Substrates of Propranolol's Effects on Drug Cue Reactivity</brief_title>
  <acronym>ProCue</acronym>
  <official_title>Neurobehavioral Substrates of Propranolol's Effects on Drug Cue Reactivity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The central objective of this project is to obtain proof-of-concept data demonstrating the&#xD;
      effects of propranolol (a beta-adrenergic antagonist) on neurobiological responses to&#xD;
      personal smoking environments and behavioral responses in a laboratory smoking behavior task.&#xD;
      Human cigarette smokers (N = 50) will take photographs of locations where they do and do not&#xD;
      smoke cigarettes. They will then be randomly assigned to receive either propranolol (40 mg)&#xD;
      or placebo prior to completing: A) An MRI session assessing neural responses to personal&#xD;
      smoking/non-smoking environments, standard smoking/non-smoking environments and proximal&#xD;
      smoking/non-smoking cues; and B) A laboratory session examining smoking behavior in response&#xD;
      to environmental cues.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 16, 2018</start_date>
  <completion_date type="Actual">July 15, 2019</completion_date>
  <primary_completion_date type="Actual">July 15, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants will be randomly assigned to receive propranolol (40 mg) or placebo</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double-blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>BOLD Activation to Smoking Cues - Amygdala</measure>
    <time_frame>MRI Scan: 2-3 hours post-administration</time_frame>
    <description>BOLD activation in amygdala (% Signal Change). These are analyzed as separate units for each Trial Type (6 total: Proximal Non-Smoking, Proximal Smoking, Standard Environment Non-Smoking, Standard Environment Smoking, Personal Environment Non-Smoking, personal Environment Smoking), MRI Run (4 total: The task was divided into 4 runs to allow for participant breaks) and Brain Hemisphere (2 total: Left and Right). These are only presented by trial type as MRI Run and Brain Hemisphere are not variables of interest.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>BOLD Activation to Smoking Cues - Anterior Insula</measure>
    <time_frame>MRI Scan: 2-3 hours post-administration</time_frame>
    <description>BOLD activation in Anterior Insula (% Signal Change). These are analyzed as separate units for each Trial Type (6 total: Proximal Non-Smoking, Proximal Smoking, Standard Environment Non-Smoking, Standard Environment Smoking, Personal Environment Non-Smoking, personal Environment Smoking), MRI Run (4 total: The task was divided into 4 runs to allow for participant breaks) and Brain Hemisphere (2 total: Left and Right). These are only presented by trial type as MRI Run and Brain Hemisphere are not variables of interest.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>BOLD Activation to Smoking Cues - Anterior Hippocampus</measure>
    <time_frame>MRI Scan: 2-3 hours post-administration</time_frame>
    <description>BOLD activation in Anterior Hippocampus (% Signal Change). These are analyzed as separate units for each Trial Type (6 total: Proximal Non-Smoking, Proximal Smoking, Standard Environment Non-Smoking, Standard Environment Smoking, Personal Environment Non-Smoking, personal Environment Smoking), MRI Run (4 total: The task was divided into 4 runs to allow for participant breaks) and Brain Hemisphere (2 total: Left and Right). These are only presented by trial type as MRI Run and Brain Hemisphere are not variables of interest.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>BOLD Activation to Smoking Cues - Posterior Hippocampus</measure>
    <time_frame>MRI Scan: 2-3 hours post-administration</time_frame>
    <description>BOLD activation in Posterior Hippocampus (% Signal Change). These are analyzed as separate units for each Trial Type (6 total: Proximal Non-Smoking, Proximal Smoking, Standard Environment Non-Smoking, Standard Environment Smoking, Personal Environment Non-Smoking, personal Environment Smoking), MRI Run (4 total: The task was divided into 4 runs to allow for participant breaks) and Brain Hemisphere (2 total: Left and Right). These are only presented by trial type as MRI Run and Brain Hemisphere are not variables of interest.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>BOLD Activation to Smoking Cues - Medial Prefrontal Cortex</measure>
    <time_frame>MRI Scan: 2-3 hours post-administration</time_frame>
    <description>BOLD activation in Medial Prefrontal Cortex (% Signal Change). These are analyzed as separate units for each Trial Type (6 total: Proximal Non-Smoking, Proximal Smoking, Standard Environment Non-Smoking, Standard Environment Smoking, Personal Environment Non-Smoking, personal Environment Smoking), MRI Run (4 total: The task was divided into 4 runs to allow for participant breaks) and Brain Hemisphere (2 total: Left and Right). These are only presented by trial type as MRI Run and Brain Hemisphere are not variables of interest.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>fMRI BOLD Connectivity</measure>
    <time_frame>MRI Scan: 2-3 hours post-administration</time_frame>
    <description>Connectivity with right amygdala when viewing proximal smoking images, using a right anterior hippocampus seed region (psychophysiological interaction analysis; PPI). Larger values represent greater connectivity between these regions while viewing proximal smoking images.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cue-Provoked Craving - Proximal Cues</measure>
    <time_frame>MRI Scan: 2-3 hours post-administration</time_frame>
    <description>During MRI Scans, participants rated their craving in response to the question &quot;While focusing on the place/object, I craved a cigarette.&quot; using a 1 (Do not agree) to 8 (Strongly agree) scale immediately following each image. Ratings were then averaged within each image category (total scale range of 1-8). Higher values represent greater craving.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cue-Provoked Craving - Standard Environment Images</measure>
    <time_frame>MRI Scan: 2-3 hours post-administration</time_frame>
    <description>During MRI Scans, participants rated their craving in response to the question &quot;While focusing on the place/object, I craved a cigarette.&quot; using a 1 (Do not agree) to 8 (Strongly agree) scale immediately following each image. Ratings were then averaged within each image category (total scale range of 1-8). Higher values represent greater craving.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cue-Provoked Craving - Personal Environment Cues</measure>
    <time_frame>MRI Scan: 2-3 hours post-administration</time_frame>
    <description>During MRI Scans, participants rated their craving in response to the question &quot;While focusing on the place/object, I craved a cigarette.&quot; using a 1 (Do not agree) to 8 (Strongly agree) scale immediately following each image. Ratings were then averaged within each image category (total scale range of 1-8). Higher values represent greater craving.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Laboratory Visit - Self-Reported Craving</measure>
    <time_frame>Lab Task: 2-3 hours post-administration</time_frame>
    <description>Self-reported craving to smoke following presentation of personal smoking environments (prior to ad-lib smoking period). Assessed using the average rating across four questions drawn from the Questionnaire on Smoking Urges: (1) While focusing on those places...nothing would have been better than smoking a cigarette; (2) While focusing on those places...I had the urge for a cigarette; (3) While focusing on those places...all I wanted right then was a cigarette; (4) While focusing on those places...I craved a cigarette. Participants rated each item on an 11-point scale ranging from 0 (Do not agree) to 100 (Strongly agree) in 10-point intervals. These ratings were averaged across items for analysis. higher values represent greater craving.&#xD;
Tiffany, S. T., &amp; Drobes, D. J. (1991). The development and initial validation of a questionnaire on smoking urges. British Journal of addiction, 86(11), 1467-1476.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Visit - # Cigarette Puffs</measure>
    <time_frame>Lab Task: 2-3 hours post-administration</time_frame>
    <description>Number of cigarette puffs taken during ad lib smoking period while participants view images of their personal smoking environment. Smoking was video recorded and puffs were coded by two raters.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Cigarette Smoking</condition>
  <arm_group>
    <arm_group_label>Propranolol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Propranolol Capsule: 40 mg IR, administered 2x at separate laboratory sessions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Capsule: No active ingredients, administered 2x at separate laboratory sessions</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propranolol</intervention_name>
    <description>Participants will take one dose of Propranolol (40mg IR) on two separate occasions.</description>
    <arm_group_label>Propranolol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants will take one dose of Placebo on two separate occasions.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Between the ages of 18 and 55&#xD;
&#xD;
          -  Generally healthy&#xD;
&#xD;
          -  Right-handed&#xD;
&#xD;
          -  Smoke &gt;= 5 cigarettes/day of a brand delivering 0.5 mg nicotine (FTC method)&#xD;
&#xD;
          -  Have been smoking regularly for &gt;= 1 year, with a stable smoking pattern over the past&#xD;
             6 months&#xD;
&#xD;
          -  Have an expired CO concentration of &gt;= 10 ppm or urinary cotinine &gt; 100 ng/ml&#xD;
&#xD;
          -  Are able to identify at least 4 smoking and 4 non-smoking enviornments&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability to attend all required sessions&#xD;
&#xD;
          -  Significant health problems that would interfere with completion of study procedures&#xD;
&#xD;
          -  Presence of conditions that would make MRI unsafe (e.g. pacemaker)&#xD;
&#xD;
          -  Presence of exclusionary psychopathology based on MINI interview (current&#xD;
             alcohol/substance use disorder moderate or severe pmild is allowable], any history of&#xD;
             bipolar disorder or psychosis). Individuals in early remission from substance use&#xD;
             disorder (not in a controlled environment) may also be allowed at the PIs discretion&#xD;
&#xD;
          -  Current use of psychoactive medications per self-report or urine screen. Certain&#xD;
             prescribed medications are allowable at the PI's discretion if appropriate&#xD;
             documentation (e.g. copy of prescription or physician letter) is provided&#xD;
&#xD;
          -  Positive breath alcohol concentraiton Pregnant, breastfeeding, or planning to become&#xD;
             pregnant during the course of study&#xD;
&#xD;
          -  Problems with vision that cannot be corrected with contacts or glasses&#xD;
&#xD;
          -  Current regular use of smokeless tobacco, smoking cessation medications or&#xD;
             non-combustible nicotine products (e.g. e-cigarettes)&#xD;
&#xD;
          -  Plans to alter smoking pattern (e.g. reduction, uptake, cessation) during course of&#xD;
             study&#xD;
&#xD;
          -  Current use of beta-adrenergic medication&#xD;
&#xD;
          -  Systolic blood pressure &lt; 90 mmHg or diastolic blood pressure &lt; 60 mmHg (sitting or&#xD;
             standing)&#xD;
&#xD;
          -  Low resting heart rate (&lt; 60 beats per minute)&#xD;
&#xD;
          -  Abnormal EKG&#xD;
&#xD;
          -  Presence of severe anemia (per complete blood count)&#xD;
&#xD;
          -  Presence of electrolyte imbalance that could impact blood pressure (per metabolic&#xD;
             panel)&#xD;
&#xD;
          -  Presence of any other contraindications for propranolol (e.g. cardiovascular disease,&#xD;
             bronchial asthma, prior allergic reaction)&#xD;
&#xD;
        Note that the above criteria reflect general guidelines for decision-making, but ultimate&#xD;
        determinations are left to the discretion of the study physician. Presence of minor (e.g.&#xD;
        asymptomatic bradycardia in the range of 50-60 in an otherwise healthy adult) or transient&#xD;
        (e.g. electrolyte imbalance readily addressed via changes in fluid intake) may still be&#xD;
        deemed eligible to participate.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jason A Oliver, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke University School of Medicine</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>October 10, 2017</study_first_submitted>
  <study_first_submitted_qc>October 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 16, 2017</study_first_posted>
  <results_first_submitted>June 25, 2020</results_first_submitted>
  <results_first_submitted_qc>July 30, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 13, 2020</results_first_posted>
  <last_update_submitted>July 30, 2020</last_update_submitted>
  <last_update_submitted_qc>July 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propranolol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Detailed protocols, datasets and additional information will be available from the Principal Investigator and research team upon request. In order to maintain compliance with HIPAA requirements (as well as university data security policies), all data will be de-identified according to HIPAA guidelines prior to being shared. Personal images themselves will not be made publicly available due to privacy concerns. However, a brief description of each image (e.g. &quot;Front porch of home&quot;) will be made available. Data would be provided in widely accessible formats (e.g. csv/xls), along with a detailed data dictionary describing all elements and coding and study protocols.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>We anticipate making data available within six months of study completion. It will be available for an indefinite period of time.</ipd_time_frame>
    <ipd_access_criteria>Contact PI for details</ipd_access_criteria>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 30, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/43/NCT03309943/ICF_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 11, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/43/NCT03309943/Prot_SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled in a laboratory setting at Duke University School of Medicine during a period ranging from January 2018 to June 2019.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Propranolol</title>
          <description>Propranolol Capsule: 40 mg IR, administered 2x at separate laboratory sessions&#xD;
Propranolol: Participants will take one dose of Propranolol (40mg IR) on two separate occasions.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo Capsule: No active ingredients, administered 2x at separate laboratory sessions&#xD;
Placebo: Participants will take one dose of Placebo on two separate occasions.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Inappropriate behavior towards staff</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Participants who completed the study.</population>
      <group_list>
        <group group_id="B1">
          <title>Propranolol</title>
          <description>Propranolol Capsule: 40 mg IR, administered 2x at separate laboratory sessions&#xD;
Propranolol: Participants will take one dose of Propranolol (40mg IR) on two separate occasions.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo Capsule: No active ingredients, administered 2x at separate laboratory sessions&#xD;
Placebo: Participants will take one dose of Placebo on two separate occasions.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="42"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.6" spread="9.6"/>
                    <measurement group_id="B2" value="35.0" spread="10.4"/>
                    <measurement group_id="B3" value="36.3" spread="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cigarettes Per Day</title>
          <description>Self-reported average number of cigarettes smoked per day at screening (baseline) visit</description>
          <units>Cigarettes/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15.0" spread="6.1"/>
                    <measurement group_id="B2" value="15.4" spread="7.3"/>
                    <measurement group_id="B3" value="15.2" spread="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fagerstrom Test for Cigarette Dependence</title>
          <description>Fagerstrom Test for Cigarette Dependence - This is an established self-report measure used to characterize the severity of nicotine dependence. Yes/no items are scored as 0 or 1 and multiple-choice items are scored from 0 to 3. These are summed to yield a total score ranging from 0 (no/minimal nicotine dependence) to 10 (severe nicotine dependence).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.2" spread="1.7"/>
                    <measurement group_id="B2" value="5.4" spread="2.2"/>
                    <measurement group_id="B3" value="4.8" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Contemplation Ladder (Motivation to Quit)</title>
          <description>Contemplation Ladder - An established single-item measure of motivation to quit smoking. Participants rate themselves on a scale ranging from 0 (No thought of quitting) to 10 (Currently taking action to quit).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.9" spread="2.5"/>
                    <measurement group_id="B2" value="3.3" spread="2.9"/>
                    <measurement group_id="B3" value="4.1" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of Previous Quit Attempts</title>
          <description>Self-reported number of previous quit attempts based on a smoking history form collected at baseline (screening) visit.</description>
          <units>quit-attempts</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.5" spread="2.3"/>
                    <measurement group_id="B2" value="2.0" spread="1.6"/>
                    <measurement group_id="B3" value="2.2" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Education</title>
          <description>Self-reported educational attainment</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Education &lt;= High School Diploma</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Education &gt; High School Diploma</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Income</title>
          <description>Self-reported USUAL annual household income.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Usual Annual Income &lt; $30,000</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Usual Annual income &gt;= $30,000</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>BOLD Activation to Smoking Cues - Amygdala</title>
        <description>BOLD activation in amygdala (% Signal Change). These are analyzed as separate units for each Trial Type (6 total: Proximal Non-Smoking, Proximal Smoking, Standard Environment Non-Smoking, Standard Environment Smoking, Personal Environment Non-Smoking, personal Environment Smoking), MRI Run (4 total: The task was divided into 4 runs to allow for participant breaks) and Brain Hemisphere (2 total: Left and Right). These are only presented by trial type as MRI Run and Brain Hemisphere are not variables of interest.</description>
        <time_frame>MRI Scan: 2-3 hours post-administration</time_frame>
        <population>Participants who completed the study. Excludes two additional participants in the placebo condition who had excessive motion artifact during scanning and could not be included in neuroimaging analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Propranolol</title>
            <description>Propranolol Capsule: 40 mg IR, administered 2x at separate laboratory sessions&#xD;
Propranolol: Participants will take one dose of Propranolol (40mg IR) on two separate occasions.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo Capsule: No active ingredients, administered 2x at separate laboratory sessions&#xD;
Placebo: Participants will take one dose of Placebo on two separate occasions.</description>
          </group>
        </group_list>
        <measure>
          <title>BOLD Activation to Smoking Cues - Amygdala</title>
          <description>BOLD activation in amygdala (% Signal Change). These are analyzed as separate units for each Trial Type (6 total: Proximal Non-Smoking, Proximal Smoking, Standard Environment Non-Smoking, Standard Environment Smoking, Personal Environment Non-Smoking, personal Environment Smoking), MRI Run (4 total: The task was divided into 4 runs to allow for participant breaks) and Brain Hemisphere (2 total: Left and Right). These are only presented by trial type as MRI Run and Brain Hemisphere are not variables of interest.</description>
          <population>Participants who completed the study. Excludes two additional participants in the placebo condition who had excessive motion artifact during scanning and could not be included in neuroimaging analyses.</population>
          <units>Percent Signal Change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Trial Type, MRI Run, Brain Hemisphere</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Trial Type, MRI Run, Brain Hemisphere</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1056"/>
                <count group_id="O2" value="864"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Non-Smoking Personal Environments</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.002471" spread="0.367038"/>
                    <measurement group_id="O2" value="0.077325" spread="0.337887"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smoking Personal Environments</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.009450" spread="0.384823"/>
                    <measurement group_id="O2" value="0.090345" spread="0.293101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Smoking Standard Environments</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.044903" spread="0.352711"/>
                    <measurement group_id="O2" value="0.042836" spread="0.341324"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smoking Standard Environments</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.111746" spread="0.321235"/>
                    <measurement group_id="O2" value="0.161114" spread="0.355927"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Smoking Proximal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.066409" spread="0.386921"/>
                    <measurement group_id="O2" value="0.015171" spread="0.353829"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smoking Proximal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.025432" spread="0.378728"/>
                    <measurement group_id="O2" value="0.133363" spread="0.409809"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Mixed model analysis examining the effects of drug condition on response to smoking vs. non-smoking cues (collapsed across category - proximal, standard environment, personal environment). Data were analyzed using the underlying raw values versus collapsing them together.</non_inferiority_desc>
            <p_value>.019</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted for FTCD. Carried out using SPSS Mixed Models with a repeated statement and compound symmetry covariance structure.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>BOLD Activation to Smoking Cues - Anterior Insula</title>
        <description>BOLD activation in Anterior Insula (% Signal Change). These are analyzed as separate units for each Trial Type (6 total: Proximal Non-Smoking, Proximal Smoking, Standard Environment Non-Smoking, Standard Environment Smoking, Personal Environment Non-Smoking, personal Environment Smoking), MRI Run (4 total: The task was divided into 4 runs to allow for participant breaks) and Brain Hemisphere (2 total: Left and Right). These are only presented by trial type as MRI Run and Brain Hemisphere are not variables of interest.</description>
        <time_frame>MRI Scan: 2-3 hours post-administration</time_frame>
        <population>Participants who completed the study. Excludes two additional participants in the placebo condition who had excessive motion artifact during scanning and could not be included in neuroimaging analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Propranolol</title>
            <description>Propranolol Capsule: 40 mg IR, administered 2x at separate laboratory sessions&#xD;
Propranolol: Participants will take one dose of Propranolol (40mg IR) on two separate occasions.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo Capsule: No active ingredients, administered 2x at separate laboratory sessions&#xD;
Placebo: Participants will take one dose of Placebo on two separate occasions.</description>
          </group>
        </group_list>
        <measure>
          <title>BOLD Activation to Smoking Cues - Anterior Insula</title>
          <description>BOLD activation in Anterior Insula (% Signal Change). These are analyzed as separate units for each Trial Type (6 total: Proximal Non-Smoking, Proximal Smoking, Standard Environment Non-Smoking, Standard Environment Smoking, Personal Environment Non-Smoking, personal Environment Smoking), MRI Run (4 total: The task was divided into 4 runs to allow for participant breaks) and Brain Hemisphere (2 total: Left and Right). These are only presented by trial type as MRI Run and Brain Hemisphere are not variables of interest.</description>
          <population>Participants who completed the study. Excludes two additional participants in the placebo condition who had excessive motion artifact during scanning and could not be included in neuroimaging analyses.</population>
          <units>Percent Signal Change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Trial Type, MRI Run, Brain Hemisphere</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Trial Type, MRI Run, Brain Hemisphere</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="176"/>
                <count group_id="O2" value="144"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Non-Smoking Personal Environments</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.179076" spread="0.288539"/>
                    <measurement group_id="O2" value="-0.157851" spread="0.281748"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smoking Personal Environments</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.127730" spread="0.293581"/>
                    <measurement group_id="O2" value="-0.142636" spread="0.269551"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Smoking Standard Environments</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.118271" spread="0.317144"/>
                    <measurement group_id="O2" value="-0.152299" spread="0.326875"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smoking Standard Environments</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.146114" spread="0.312662"/>
                    <measurement group_id="O2" value="-0.149887" spread="0.282468"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Smoking Proximal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.085715" spread="0.331652"/>
                    <measurement group_id="O2" value="-0.085873" spread="0.270967"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smoking Proximal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.086867" spread="0.352310"/>
                    <measurement group_id="O2" value="-0.098181" spread="0.318646"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Mixed model analysis examining the effects of drug condition on response to smoking vs. non-smoking cues (collapsed across category - proximal, standard environment, personal environment). Data were analyzed using the underlying raw values versus collapsing them together.</non_inferiority_desc>
            <p_value>.830</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted for FTCD</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>BOLD Activation to Smoking Cues - Anterior Hippocampus</title>
        <description>BOLD activation in Anterior Hippocampus (% Signal Change). These are analyzed as separate units for each Trial Type (6 total: Proximal Non-Smoking, Proximal Smoking, Standard Environment Non-Smoking, Standard Environment Smoking, Personal Environment Non-Smoking, personal Environment Smoking), MRI Run (4 total: The task was divided into 4 runs to allow for participant breaks) and Brain Hemisphere (2 total: Left and Right). These are only presented by trial type as MRI Run and Brain Hemisphere are not variables of interest.</description>
        <time_frame>MRI Scan: 2-3 hours post-administration</time_frame>
        <population>Participants who completed the study. Excludes two additional participants in the placebo condition who had excessive motion artifact during scanning and could not be included in neuroimaging analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Propranolol</title>
            <description>Propranolol Capsule: 40 mg IR, administered 2x at separate laboratory sessions&#xD;
Propranolol: Participants will take one dose of Propranolol (40mg IR) on two separate occasions.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo Capsule: No active ingredients, administered 2x at separate laboratory sessions&#xD;
Placebo: Participants will take one dose of Placebo on two separate occasions.</description>
          </group>
        </group_list>
        <measure>
          <title>BOLD Activation to Smoking Cues - Anterior Hippocampus</title>
          <description>BOLD activation in Anterior Hippocampus (% Signal Change). These are analyzed as separate units for each Trial Type (6 total: Proximal Non-Smoking, Proximal Smoking, Standard Environment Non-Smoking, Standard Environment Smoking, Personal Environment Non-Smoking, personal Environment Smoking), MRI Run (4 total: The task was divided into 4 runs to allow for participant breaks) and Brain Hemisphere (2 total: Left and Right). These are only presented by trial type as MRI Run and Brain Hemisphere are not variables of interest.</description>
          <population>Participants who completed the study. Excludes two additional participants in the placebo condition who had excessive motion artifact during scanning and could not be included in neuroimaging analyses.</population>
          <units>Percent Signal Change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Trial Type, MRI Run, Brain Hemisphere</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Trial Type, MRI Run, Brain Hemisphere</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="176"/>
                <count group_id="O2" value="144"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Non-Smoking Personal Environments</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.061001" spread="0.324934"/>
                    <measurement group_id="O2" value="0.095120" spread="0.271027"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smoking Personal Environments</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.073925" spread="0.300800"/>
                    <measurement group_id="O2" value="0.088399" spread="0.267232"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Smoking Standard Environments</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.133369" spread="0.315323"/>
                    <measurement group_id="O2" value="0.083638" spread="0.277520"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smoking Standard Environments</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.171673" spread="0.289132"/>
                    <measurement group_id="O2" value="0.186590" spread="0.300916"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Smoking Proximal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.088852" spread="0.323655"/>
                    <measurement group_id="O2" value="0.000827" spread="0.280219"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smoking Proximal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.024626" spread="0.296327"/>
                    <measurement group_id="O2" value="0.095598" spread="0.291577"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Mixed model analysis examining the effects of drug condition on response to smoking vs. non-smoking cues (collapsed across category - proximal, standard environment, personal environment). Data were analyzed using the underlying raw values versus collapsing them together.</non_inferiority_desc>
            <p_value>.006</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>BOLD Activation to Smoking Cues - Posterior Hippocampus</title>
        <description>BOLD activation in Posterior Hippocampus (% Signal Change). These are analyzed as separate units for each Trial Type (6 total: Proximal Non-Smoking, Proximal Smoking, Standard Environment Non-Smoking, Standard Environment Smoking, Personal Environment Non-Smoking, personal Environment Smoking), MRI Run (4 total: The task was divided into 4 runs to allow for participant breaks) and Brain Hemisphere (2 total: Left and Right). These are only presented by trial type as MRI Run and Brain Hemisphere are not variables of interest.</description>
        <time_frame>MRI Scan: 2-3 hours post-administration</time_frame>
        <population>Participants who completed the study. Excludes two additional participants in the placebo condition who had excessive motion artifact during scanning and could not be included in neuroimaging analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Propranolol</title>
            <description>Propranolol Capsule: 40 mg IR, administered 2x at separate laboratory sessions&#xD;
Propranolol: Participants will take one dose of Propranolol (40mg IR) on two separate occasions.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo Capsule: No active ingredients, administered 2x at separate laboratory sessions&#xD;
Placebo: Participants will take one dose of Placebo on two separate occasions.</description>
          </group>
        </group_list>
        <measure>
          <title>BOLD Activation to Smoking Cues - Posterior Hippocampus</title>
          <description>BOLD activation in Posterior Hippocampus (% Signal Change). These are analyzed as separate units for each Trial Type (6 total: Proximal Non-Smoking, Proximal Smoking, Standard Environment Non-Smoking, Standard Environment Smoking, Personal Environment Non-Smoking, personal Environment Smoking), MRI Run (4 total: The task was divided into 4 runs to allow for participant breaks) and Brain Hemisphere (2 total: Left and Right). These are only presented by trial type as MRI Run and Brain Hemisphere are not variables of interest.</description>
          <population>Participants who completed the study. Excludes two additional participants in the placebo condition who had excessive motion artifact during scanning and could not be included in neuroimaging analyses.</population>
          <units>Percent Signal Change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Trial Type, MRI Run, Brain Hemisphere</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Trial Type, MRI Run, Brain Hemisphere</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="176"/>
                <count group_id="O2" value="144"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Non-Smoking Personal Environments</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.161077" spread="0.288481"/>
                    <measurement group_id="O2" value="0.185521" spread="0.262021"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smoking Personal Environments</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.156684" spread="0.303924"/>
                    <measurement group_id="O2" value="0.166154" spread="0.252282"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Smoking Standard Environments</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.137124" spread="0.304769"/>
                    <measurement group_id="O2" value="0.161655" spread="0.241679"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smoking Standard Environments</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.179651" spread="0.256910"/>
                    <measurement group_id="O2" value="0.176196" spread="0.269538"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Smoking Proximal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.056247" spread="0.281092"/>
                    <measurement group_id="O2" value="0.053026" spread="0.271871"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smoking Proximal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.050077" spread="0.260461"/>
                    <measurement group_id="O2" value="0.121240" spread="0.262651"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Mixed model analysis examining the effects of drug condition on response to smoking vs. non-smoking cues (collapsed across category - proximal, standard environment, personal environment). Data were analyzed using the underlying raw values versus collapsing them together.</non_inferiority_desc>
            <p_value>.653</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>BOLD Activation to Smoking Cues - Medial Prefrontal Cortex</title>
        <description>BOLD activation in Medial Prefrontal Cortex (% Signal Change). These are analyzed as separate units for each Trial Type (6 total: Proximal Non-Smoking, Proximal Smoking, Standard Environment Non-Smoking, Standard Environment Smoking, Personal Environment Non-Smoking, personal Environment Smoking), MRI Run (4 total: The task was divided into 4 runs to allow for participant breaks) and Brain Hemisphere (2 total: Left and Right). These are only presented by trial type as MRI Run and Brain Hemisphere are not variables of interest.</description>
        <time_frame>MRI Scan: 2-3 hours post-administration</time_frame>
        <population>Participants who completed the study. Excludes two additional participants in the placebo condition who had excessive motion artifact during scanning and could not be included in neuroimaging analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Propranolol</title>
            <description>Propranolol Capsule: 40 mg IR, administered 2x at separate laboratory sessions&#xD;
Propranolol: Participants will take one dose of Propranolol (40mg IR) on two separate occasions.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo Capsule: No active ingredients, administered 2x at separate laboratory sessions&#xD;
Placebo: Participants will take one dose of Placebo on two separate occasions.</description>
          </group>
        </group_list>
        <measure>
          <title>BOLD Activation to Smoking Cues - Medial Prefrontal Cortex</title>
          <description>BOLD activation in Medial Prefrontal Cortex (% Signal Change). These are analyzed as separate units for each Trial Type (6 total: Proximal Non-Smoking, Proximal Smoking, Standard Environment Non-Smoking, Standard Environment Smoking, Personal Environment Non-Smoking, personal Environment Smoking), MRI Run (4 total: The task was divided into 4 runs to allow for participant breaks) and Brain Hemisphere (2 total: Left and Right). These are only presented by trial type as MRI Run and Brain Hemisphere are not variables of interest.</description>
          <population>Participants who completed the study. Excludes two additional participants in the placebo condition who had excessive motion artifact during scanning and could not be included in neuroimaging analyses.</population>
          <units>Percent Signal Change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Trial Type, MRI Run, Brain Hemisphere</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Trial Type, MRI Run, Brain Hemisphere</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="176"/>
                <count group_id="O2" value="144"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Non-Smoking Personal Environments</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.033030" spread="0.322540"/>
                    <measurement group_id="O2" value="0.012705" spread="0.409304"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smoking Personal Environments</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.058184" spread="0.378236"/>
                    <measurement group_id="O2" value="0.060320" spread="0.313844"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Smoking Standard Environments</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.078483" spread="0.350182"/>
                    <measurement group_id="O2" value="-0.167025" spread="0.447513"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smoking Standard Environments</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.068693" spread="0.311347"/>
                    <measurement group_id="O2" value="-0.093598" spread="0.447743"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Smoking Proximal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.039529" spread="0.362686"/>
                    <measurement group_id="O2" value="-0.109172" spread="0.422732"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smoking Proximal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.064034" spread="0.345958"/>
                    <measurement group_id="O2" value="0.015524" spread="0.413311"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Mixed model analysis examining the effects of drug condition on response to smoking vs. non-smoking cues (collapsed across category - proximal, standard environment, personal environment). Data were analyzed using the underlying raw values versus collapsing them together.</non_inferiority_desc>
            <p_value>.012</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted for FTCD</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>fMRI BOLD Connectivity</title>
        <description>Connectivity with right amygdala when viewing proximal smoking images, using a right anterior hippocampus seed region (psychophysiological interaction analysis; PPI). Larger values represent greater connectivity between these regions while viewing proximal smoking images.</description>
        <time_frame>MRI Scan: 2-3 hours post-administration</time_frame>
        <population>Participants who completed the study. Excludes two additional participants in the placebo condition who had excessive motion artifact during scanning and could not be included in neuroimaging analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Propranolol</title>
            <description>Propranolol Capsule: 40 mg IR, administered 2x at separate laboratory sessions&#xD;
Propranolol: Participants will take one dose of Propranolol (40mg IR) on two separate occasions.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo Capsule: No active ingredients, administered 2x at separate laboratory sessions&#xD;
Placebo: Participants will take one dose of Placebo on two separate occasions.</description>
          </group>
        </group_list>
        <measure>
          <title>fMRI BOLD Connectivity</title>
          <description>Connectivity with right amygdala when viewing proximal smoking images, using a right anterior hippocampus seed region (psychophysiological interaction analysis; PPI). Larger values represent greater connectivity between these regions while viewing proximal smoking images.</description>
          <population>Participants who completed the study. Excludes two additional participants in the placebo condition who had excessive motion artifact during scanning and could not be included in neuroimaging analyses.</population>
          <units>PPI Index</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0740" spread="0.0769"/>
                    <measurement group_id="O2" value="0.0228" spread="0.0997"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Mixed model analysis examining the effects of drug condition on PPI indexes while viewing proximal smoking cues (which drove activation effects).</non_inferiority_desc>
            <p_value>.013</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cue-Provoked Craving - Proximal Cues</title>
        <description>During MRI Scans, participants rated their craving in response to the question &quot;While focusing on the place/object, I craved a cigarette.&quot; using a 1 (Do not agree) to 8 (Strongly agree) scale immediately following each image. Ratings were then averaged within each image category (total scale range of 1-8). Higher values represent greater craving.</description>
        <time_frame>MRI Scan: 2-3 hours post-administration</time_frame>
        <population>Participants who completed the study. Excludes two additional participants in the placebo condition who had excessive motion artifact during scanning and could not be included in neuroimaging analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Propranolol</title>
            <description>Propranolol Capsule: 40 mg IR, administered 2x at separate laboratory sessions&#xD;
Propranolol: Participants will take one dose of Propranolol (40mg IR) on two separate occasions.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo Capsule: No active ingredients, administered 2x at separate laboratory sessions&#xD;
Placebo: Participants will take one dose of Placebo on two separate occasions.</description>
          </group>
        </group_list>
        <measure>
          <title>Cue-Provoked Craving - Proximal Cues</title>
          <description>During MRI Scans, participants rated their craving in response to the question &quot;While focusing on the place/object, I craved a cigarette.&quot; using a 1 (Do not agree) to 8 (Strongly agree) scale immediately following each image. Ratings were then averaged within each image category (total scale range of 1-8). Higher values represent greater craving.</description>
          <population>Participants who completed the study. Excludes two additional participants in the placebo condition who had excessive motion artifact during scanning and could not be included in neuroimaging analyses.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Non-Smoking</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.866883" spread="1.566946"/>
                    <measurement group_id="O2" value="1.898148" spread="0.824614"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smoking</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.103084" spread="1.618450"/>
                    <measurement group_id="O2" value="6.547619" spread="1.685597"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Repeated Measures ANCOVA analysis examining condition differences (adjusting for FTCD score)</non_inferiority_desc>
            <p_value>.024</p_value>
            <method>Repeated Measures ANCOVA</method>
            <method_desc>Adjusted for FTCD.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cue-Provoked Craving - Standard Environment Images</title>
        <description>During MRI Scans, participants rated their craving in response to the question &quot;While focusing on the place/object, I craved a cigarette.&quot; using a 1 (Do not agree) to 8 (Strongly agree) scale immediately following each image. Ratings were then averaged within each image category (total scale range of 1-8). Higher values represent greater craving.</description>
        <time_frame>MRI Scan: 2-3 hours post-administration</time_frame>
        <population>Participants who completed the study. Excludes two additional participants in the placebo condition who had excessive motion artifact during scanning and could not be included in neuroimaging analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Propranolol</title>
            <description>Propranolol Capsule: 40 mg IR, administered 2x at separate laboratory sessions&#xD;
Propranolol: Participants will take one dose of Propranolol (40mg IR) on two separate occasions.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo Capsule: No active ingredients, administered 2x at separate laboratory sessions&#xD;
Placebo: Participants will take one dose of Placebo on two separate occasions.</description>
          </group>
        </group_list>
        <measure>
          <title>Cue-Provoked Craving - Standard Environment Images</title>
          <description>During MRI Scans, participants rated their craving in response to the question &quot;While focusing on the place/object, I craved a cigarette.&quot; using a 1 (Do not agree) to 8 (Strongly agree) scale immediately following each image. Ratings were then averaged within each image category (total scale range of 1-8). Higher values represent greater craving.</description>
          <population>Participants who completed the study. Excludes two additional participants in the placebo condition who had excessive motion artifact during scanning and could not be included in neuroimaging analyses.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Non-Smoking</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.673052" spread="1.681618"/>
                    <measurement group_id="O2" value="1.763889" spread="0.644389"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smoking</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.666937" spread="1.588874"/>
                    <measurement group_id="O2" value="4.868056" spread="1.716846"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Repeated Measures ANCOVA analysis examining condition differences (adjusting for FTCD score)</non_inferiority_desc>
            <p_value>.086</p_value>
            <method>Repeated Measures ANCOVA</method>
            <method_desc>Adjusted for FTCD score</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cue-Provoked Craving - Personal Environment Cues</title>
        <description>During MRI Scans, participants rated their craving in response to the question &quot;While focusing on the place/object, I craved a cigarette.&quot; using a 1 (Do not agree) to 8 (Strongly agree) scale immediately following each image. Ratings were then averaged within each image category (total scale range of 1-8). Higher values represent greater craving.</description>
        <time_frame>MRI Scan: 2-3 hours post-administration</time_frame>
        <population>Participants who completed the study. Excludes two additional participants in the placebo condition who had excessive motion artifact during scanning and could not be included in neuroimaging analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Propranolol</title>
            <description>Propranolol Capsule: 40 mg IR, administered 2x at separate laboratory sessions&#xD;
Propranolol: Participants will take one dose of Propranolol (40mg IR) on two separate occasions.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo Capsule: No active ingredients, administered 2x at separate laboratory sessions&#xD;
Placebo: Participants will take one dose of Placebo on two separate occasions.</description>
          </group>
        </group_list>
        <measure>
          <title>Cue-Provoked Craving - Personal Environment Cues</title>
          <description>During MRI Scans, participants rated their craving in response to the question &quot;While focusing on the place/object, I craved a cigarette.&quot; using a 1 (Do not agree) to 8 (Strongly agree) scale immediately following each image. Ratings were then averaged within each image category (total scale range of 1-8). Higher values represent greater craving.</description>
          <population>Participants who completed the study. Excludes two additional participants in the placebo condition who had excessive motion artifact during scanning and could not be included in neuroimaging analyses.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Non-Smoking</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.369318" spread="1.802147"/>
                    <measurement group_id="O2" value="2.965278" spread="1.668703"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smoking</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.045996" spread="1.457661"/>
                    <measurement group_id="O2" value="6.638889" spread="1.569405"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Repeated Measures ANCOVA analysis examining condition differences (adjusting for FTCD score)</non_inferiority_desc>
            <p_value>.140</p_value>
            <method>Repeated Measures ANCOVA</method>
            <method_desc>Adjusted for FTCD score</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Laboratory Visit - Self-Reported Craving</title>
        <description>Self-reported craving to smoke following presentation of personal smoking environments (prior to ad-lib smoking period). Assessed using the average rating across four questions drawn from the Questionnaire on Smoking Urges: (1) While focusing on those places...nothing would have been better than smoking a cigarette; (2) While focusing on those places...I had the urge for a cigarette; (3) While focusing on those places...all I wanted right then was a cigarette; (4) While focusing on those places...I craved a cigarette. Participants rated each item on an 11-point scale ranging from 0 (Do not agree) to 100 (Strongly agree) in 10-point intervals. These ratings were averaged across items for analysis. higher values represent greater craving.&#xD;
Tiffany, S. T., &amp; Drobes, D. J. (1991). The development and initial validation of a questionnaire on smoking urges. British Journal of addiction, 86(11), 1467-1476.</description>
        <time_frame>Lab Task: 2-3 hours post-administration</time_frame>
        <population>Participants who completed the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Propranolol</title>
            <description>Propranolol Capsule: 40 mg IR, administered 2x at separate laboratory sessions&#xD;
Propranolol: Participants will take one dose of Propranolol (40mg IR) on two separate occasions.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo Capsule: No active ingredients, administered 2x at separate laboratory sessions&#xD;
Placebo: Participants will take one dose of Placebo on two separate occasions.</description>
          </group>
        </group_list>
        <measure>
          <title>Laboratory Visit - Self-Reported Craving</title>
          <description>Self-reported craving to smoke following presentation of personal smoking environments (prior to ad-lib smoking period). Assessed using the average rating across four questions drawn from the Questionnaire on Smoking Urges: (1) While focusing on those places...nothing would have been better than smoking a cigarette; (2) While focusing on those places...I had the urge for a cigarette; (3) While focusing on those places...all I wanted right then was a cigarette; (4) While focusing on those places...I craved a cigarette. Participants rated each item on an 11-point scale ranging from 0 (Do not agree) to 100 (Strongly agree) in 10-point intervals. These ratings were averaged across items for analysis. higher values represent greater craving.&#xD;
Tiffany, S. T., &amp; Drobes, D. J. (1991). The development and initial validation of a questionnaire on smoking urges. British Journal of addiction, 86(11), 1467-1476.</description>
          <population>Participants who completed the study.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.3" spread="2.7"/>
                    <measurement group_id="O2" value="7.9" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Standard ANCOVA analysis examining condition differences (adjusting for baseline craving and FTCD score).</non_inferiority_desc>
            <p_value>.556</p_value>
            <method>ANCOVA</method>
            <method_desc>Adjusted for baseline craving and FTCD score</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Laboratory Visit - # Cigarette Puffs</title>
        <description>Number of cigarette puffs taken during ad lib smoking period while participants view images of their personal smoking environment. Smoking was video recorded and puffs were coded by two raters.</description>
        <time_frame>Lab Task: 2-3 hours post-administration</time_frame>
        <population>Participants who completed the study. Data from one participant in the placebo condition was lost due to technical problems with the recording.</population>
        <group_list>
          <group group_id="O1">
            <title>Propranolol</title>
            <description>Propranolol Capsule: 40 mg IR, administered 2x at separate laboratory sessions&#xD;
Propranolol: Participants will take one dose of Propranolol (40mg IR) on two separate occasions.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo Capsule: No active ingredients, administered 2x at separate laboratory sessions&#xD;
Placebo: Participants will take one dose of Placebo on two separate occasions.</description>
          </group>
        </group_list>
        <measure>
          <title>Laboratory Visit - # Cigarette Puffs</title>
          <description>Number of cigarette puffs taken during ad lib smoking period while participants view images of their personal smoking environment. Smoking was video recorded and puffs were coded by two raters.</description>
          <population>Participants who completed the study. Data from one participant in the placebo condition was lost due to technical problems with the recording.</population>
          <units>Puffs</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.2" spread="7.1"/>
                    <measurement group_id="O2" value="17.7" spread="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Standard ANCOVA analysis examining condition differences (adjusting for FTCD score).</non_inferiority_desc>
            <p_value>.463</p_value>
            <p_value_desc>Adjusted for FTCD score only.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>This is an acute administration study with an approved medication with a well-established safety profile. Adverse events were assessed over the 1-3 month period in which participants were engaged in the project, primarily for purposes of ensuring new contraindications did not emerge prior to drug administration vs concerns about adverse events related to the drug itself.</time_frame>
      <desc>Participants abstain from smoking for 24 hours before the MRI visit and 6 hours before the laboratory visit. Symptoms of nicotine withdrawal are assessed but are not considered adverse events. Participant self-report of any newly-onset or worsening medical problems during their time of participation are considered adverse events. Repeat blood draws were occasionally necessary but are also not considered adverse events.</desc>
      <group_list>
        <group group_id="E1">
          <title>Propranolol</title>
          <description>Propranolol Capsule: 40 mg IR, administered 2x at separate laboratory sessions&#xD;
Propranolol: Participants will take one dose of Propranolol (40mg IR) on two separate occasions.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo Capsule: No active ingredients, administered 2x at separate laboratory sessions&#xD;
Placebo: Participants will take one dose of Placebo on two separate occasions.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Wrist Injury</sub_title>
                <description>Participant arrived to MRI appointment in a wrist brace and reported they had sprained their wrist two days prior to the appointment.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dog Bite</sub_title>
                <description>Participant reported having been bitten by a dog prior to their MRI visit.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This was a pilot study with a small sample size. A between-subjects design was used with no baseline scan for comparison. No clinical endpoints were examined - results are limited to neuroimaging and behavioral task outcomes.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Jason A. Oliver, Ph.D.</name_or_title>
      <organization>Duke University School of Medicine</organization>
      <phone>(919) 668-0093</phone>
      <email>Jason.A.Oliver@duke.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

